Nu Spasm

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nu Spasm

What is Nu Spasm?

Nu Spasm is a pharmacological intervention categorized as an antispasmodic medication. It is primarily utilized to manage symptoms associated with various gastrointestinal motility disorders. The formulation is designed to target the smooth muscles of the digestive tract, helping to alleviate functional disturbances that lead to discomfort.

Mechanism of Action

The active components in Nu Spasm work by inhibiting the action of acetylcholine on muscarinic receptors located within the smooth muscles of the gastrointestinal system. By blocking these signals, the medication reduces involuntary muscle contractions and spasms. This relaxation of the intestinal wall helps to normalize the movement of the digestive system and provides relief from cramp-like sensations.

Clinical Applications

Nu Spasm is commonly used in the management of functional bowel disturbances. Its application is focused on addressing symptoms such as:

  • Abdominal cramping and pain related to muscle spasms.
  • Discomfort associated with irritable bowel syndrome (IBS).
  • Gastrointestinal distress characterized by hypermotility.

Characteristics and Use Cases

As a non-systemic or targeted antispasmodic, Nu Spasm is chosen for its specific affinity for the digestive tract's musculature. It is typically employed when smooth muscle hyperactivity is identified as the underlying cause of a patient's physical discomfort. The medication is intended to provide symptomatic relief rather than addressing inflammatory or infectious causes of gastrointestinal distress.

Regulatory References

  1. WHO Essential Medicines List entry

What side effects are possible with Nu Spasm?

Nu Spasm (a combination product containing an antispasmodic and paracetamol/acetaminophen) has a safety profile characterized by anticholinergic and pain-relieving component risks. Regulatory documents categorize the most common adverse reactions as those affecting the nervous system (e.g., dizziness, sleepiness, blurred vision) and the gastrointestinal tract (e.g., dry mouth, nausea, constipation, diarrhea, flatulence).

Serious Adverse Reactions and Safety Restrictions

Category Key Safety Consideration
Hepatotoxicity Risk Overdose, particularly due to the Paracetamol/Acetaminophen component, carries a serious, well-documented risk of liver damage. Concomitant use with alcohol may increase this risk. The maximum recommended daily dosage of Paracetamol must not be exceeded.
Hypersensitivity Allergic reactions, including skin rashes and hives, and in rare cases, severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported with the use of Paracetamol-containing products.
Contraindications Use is strictly avoided in patients with a known allergy to any component, severe liver disease, obstructive diseases of the gastrointestinal or urinary tracts, uncorrected narrow-angle glaucoma, and myasthenia gravis.
Population-Specific Caution is advised in patients with heart conditions, an enlarged prostate, or kidney impairment. Due to potential risks, the combination is generally not recommended for use in children under 12 years of age.

Patients are advised that this medicine may cause visual disturbances and dizziness, which can impair the ability to operate machinery or drive. These effects require caution until the individual response to the medication is known.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory documents define the overdose profile of Nu Spasm by listing the expected manifestations of exaggerated peripheral anticholinergic effects. These officially documented clinical signs include a fast heart rate (tachycardia), difficulty passing urine (urinary retention), reddening of the skin, dry mouth, and transient visual disturbances, such as blurred vision. Severe systemic outcomes reported in official documentation following high exposure levels, though rare, involve central nervous system effects such as confusion, agitation, hallucinations, and coma. Respiratory paralysis and Cheynes-Stokes respiration have also been noted in the context of overdosage.

The official regulatory guidance mandates a clear requirement for seeking help. Immediate medical attention must be sought for any suspected overdose or at the first sign of an adverse reaction. Additionally, medical advice should be immediately sought if severe, unexplained abdominal pain persists or worsens or is accompanied by systemic symptoms like fever, vomiting, or fainting. Overdosage symptoms are officially documented to respond to parasympathomimetics. Management procedures described in regulatory sources for oral poisoning include gastric lavage with medicinal charcoal followed by magnesium sulfate, and catheterisation may be required for urinary retention. Geriatric patients may be particularly susceptible to the anticholinergic side effects, experiencing confusion or excitement.

Therapeutic Uses of Nu Spasm

What Nu Spasm treats: main uses and benefits

Nu Spasm, which contains the active ingredient hyoscine butylbromide, is commonly used to help with symptoms related to physical discomfort linked to organ-specific functional stress. It is applied across domains where additional symptomatic support is needed as an antispasmodic medication.

The medication's core function is to contribute to easing symptoms related to inflammatory or irritative states and is applied in situations involving certain distressing symptoms. It is considered relevant in conditions characterized by periods of heightened symptoms. The medicine is applied in addressing symptom clusters that may become intense or disruptive, such as those associated with acute or disruptive episodes like renal (kidney) colic or biliary (gallbladder) colic, and supports patients during diagnostic procedures like pyelography or gastroduodenal endoscopy.

This support is relevant in contexts involving heightened systemic burden and may assist with maintaining functional stability. This support is commonly used across conditions presenting with acute episodes. “provides support that helps ease the overall symptom burden”. The medication helps improve day-to-day comfort during symptomatic periods, offering symptomatic relief that helps patients cope more steadily when symptoms intensify.

Quick Fact: Helps Manage Spasm-Related Discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Nu Spasm?

The population eligibility for Nu Spasm (Hyoscine Butylbromide) is strictly defined by regulatory documents, distinguishing between approved, restricted, and prohibited groups. The medicine is primarily permitted for use in adults and children aged 6 years and over for oral tablet formulations. The injectable form is generally intended for adults.

Contraindications and Prohibited Populations

Use is absolutely contraindicated (must not be used) in patients with specific preexisting conditions due to the risk of serious complications. These conditions include Untreated Narrow Angle Glaucoma, Myasthenia Gravis, Paralytic or Obstructive Ileus, Megacolon, and Mechanical Stenosis in the gastrointestinal tract. Hypersensitivity to the active substance or excipients also defines ineligibility.

Conditional Use and Restrictions

Population Group Regulatory Status
Children under 6 years Not recommended for oral use.
Pregnancy Not recommended as a precautionary measure due to limited human data.
Lactation (Breastfeeding) Not recommended due to insufficient data on excretion into human milk.
Anticoagulant Use Intramuscular injection is prohibited (risk of hematoma).

Use requires caution in patients prone to Tachyarrhythmias or with Prostatic Hypertrophy.

What should I know about interactions with other medicines?

The interaction profile for Nu Spasm, which contains hyoscine butylbromide, is primarily defined by the potential for pharmacodynamic reinforcement and specific administration restrictions. Co-administration with certain medication classes may result in an additive intensification of the anticholinergic effect. This applies to agents such as tri- and tetracyclic antidepressants, certain antihistamines, antipsychotics, and other drugs like quinidine or amantadine. The official label also notes that beta-adrenergic agents may have their tachycardic effects enhanced.

Interactions also occur with medicines that affect gastrointestinal motility. Concomitant use with dopamine antagonists, such as metoclopramide, can lead to the diminution of the effects of both drugs on the digestive tract. Because the medicine reduces gut motility, the absorption and systemic effect of other concurrently administered oral medications may be officially delayed or altered. To mitigate this risk, antacids or adsorbent anti-diarrheals require a minimum one-hour separation in administration time.

A key procedural restriction is officially documented: the medicine must not be administered by intramuscular injection when the patient is concurrently taking anticoagulant drugs, due to the specific risk of intramuscular haematoma. The regulatory documentation also advises against co-administration with alcohol, as this substance may increase the chance of side effects such as drowsiness or dizziness.

Mechanism of Action

Targeted Blockade of Muscarinic Receptors

Nu Spasm's action is defined by a specific mechanism that interrupts the nerve signals responsible for involuntary muscle contraction, with action concentrated on the smooth muscles of the digestive, biliary, and urinary tracts. The primary mechanism involves competitive antagonism at the muscarinic cholinergic receptors (M-receptors), particularly the M3 subtype, which are essential for initiating smooth muscle contraction. The molecule binds to these receptors, temporarily occupying them and preventing the neurotransmitter Acetylcholine (ACh) from activating the contraction signal. This directly modulates the cholinergic pathway.

Visceral Spasmolysis through Calcium Dynamics

This receptor blockade initiates a cascade that directly influences the mechanics of the muscle cell. By blocking the M3 receptor, the internal chemical signal that prompts the release of intracellular calcium ( Ca^2+) is suppressed. Since calcium is essential for the muscle fiber to tense or contract, this suppression leads to spasmolysis—the relaxation of the smooth muscle—which is the resulting physiological effect.

Restricted Peripheral Pathway Interference

Hyoscine Butylbromide's quaternary ammonium structure enables an exclusively peripheral action. This prevents effective absorption into the central nervous system, localizing its anticholinergic effect to the organs of the abdominal and pelvic viscera. The focused spasmolytic mechanism acts where the contraction originates without engaging central pathways.

Dosage and Administration Information

Nu Spasm, which contains hyoscine butylbromide, is administered using two primary dosage forms: 10 mg film-coated tablets for oral intake and a 20 mg/mL solution for parenteral use. The instructions for use are defined by administration, dosing, and procedural parameters.

Instruction Category Administration Details
Route of administration Approved for Oral, Intravenous (IV), Intramuscular (IM), or Subcutaneous (SC) injection.
Dosing schedule Adult Oral: 10 mg to 20 mg repeated up to 4 times daily. Adult Parenteral (Acute): 20 mg, repeated after 30 minutes (Max 100 mg daily).
Timing in relation to meals May be taken with or without food.
Preparation requirements Injection solution may be diluted with glucose or sodium chloride 0.9% solution.
Age-group administration rules Children 6–12 years (Oral): 10 mg 3 times daily. Use not recommended for children under 6 years.
Special procedural conditions Oral: Tablets must be swallowed whole and not crushed. IV: Must be administered slowly.

This framework defines the parameters for administering Hyoscine Butylbromide. The difference in routes supports either routine multiple-daily use (oral) or acute intermittent use (parenteral), controlling the maximum quantity and repetition interval. The use is constrained to short-term episodes, as the medicine is not indicated for continuous daily use or extended periods without proper medical investigation. These instructions standardize the precise manner of application.

Recent Clinical Evidence

Evidence for Abdominal Cramping and Pain Associated with IBS

Research explored the use of Hyoscine Butylbromide in studies examining outcomes related to physical discomfort and episodic changes in patients with cramping pain, often linked to Irritable Bowel Syndrome (IBS). These studies, primarily Randomized Controlled Trials (RCTs), evaluated changes in pain intensity using standardized scales and the frequency of cramping episodes in adults and older children. Studies monitored measured data regarding pain scores when compared against an inactive control. Regulatory analyses describe patterns related to clinical experience and post-marketing surveillance for this indication. Long-term effects are not fully established, and evidence exploring use across different IBS subtypes is limited.


Evidence for Use in Acute Colic and Organ Spasm

The research for acute spasms, such as those related to kidney (renal colic) and gallbladder (biliary colic), was evaluated in studies using the injectable form. Short-term RCTs, conducted during periods of increased symptom activity, monitored outcomes describing episodic or acute changes in patients presenting with physiological strain. Research describes patterns related to symptom measurements at very short intervals. Studies explored how the change in pain scores compared with other agents and monitored the need for rescue pain medication, though findings related to this need were observed to vary. Data remain uncertain regarding the medicine's influence on objective outcomes, such as the rate of kidney stone passage.


Evidence as a Procedural Aid in Diagnostic Imaging

The medicine was evaluated in research examining its role in assisting certain diagnostic and therapeutic procedures. Studies focused on technical outcomes, such as the quality of the image produced, and procedural metrics, such as the reported ease and duration of the examination. Research describes patterns related to smooth muscle relaxation that assists with organ visualization. However, research highlights that studies primarily focused on technical success metrics and did not often include direct measurement of patient-reported functional outcomes. Findings regarding measured changes in procedure time were reported to be mixed or inconsistent across different research reports.


Research Gaps and Uncertainty

Evidence quality varies across studies, and many trials are focused on acute or short-term effects, meaning follow-up durations were limited in the primary trials. Long-term effects are not fully established and are not well characterized in the main published research. Evidence exploring use in pediatric populations and patients with significant comorbidities remains insufficient, and certain comparative evidence is lacking or inconclusive.

Key Studies & References

  1. WHO Model List of Essential Medicines – 22nd List (2021) (Guideline/Authority)

Frequently Asked Questions (FAQ)

Common questions about Nu Spasm (FAQ)


Q: Can Nu Spasm be used for muscle spasms in the back?

According to official regulatory documents, the medicine is indicated for smooth muscle spasms occurring in visceral organs, specifically the gastrointestinal, biliary, and genitourinary tracts. This focus means its primary approved use is for internal cramping, known as visceral spasm.


Q: Are there any common over-the-counter pain relievers that interact with Nu Spasm?

Official information notes that co-administration with other paracetamol-containing products should be managed due to the risk of liver damage. Additionally, interactions are often described by drug class, warning of potential additive anticholinergic effects when combined with certain agents.


Q: Can people who take blood pressure medication use Nu Spasm?

The official documentation advises caution for individuals with pre-existing heart conditions. It is also noted that the tachycardic effects (increased heart rate) of beta-adrenergic agents—a class of blood pressure medicine—may be enhanced when used together with Nu Spasm.


Q: What does it mean if an official document says Nu Spasm is 'contraindicated' for a condition?

The regulatory term contraindication means that the medicine must not be used by a patient who has the specified condition. This designation is given when using the medicine could lead to a serious health risk or complication.


Q: How is Nu Spasm different from other treatments for similar conditions?

Studies indicate that Nu Spasm is classified as a peripheral antispasmodic due to its unique chemical structure. This structure prevents the medicine from effectively crossing into the central nervous system, meaning its action is localized to the organs of the viscera.


Q: Why might a doctor prescribe Nu Spasm instead of another treatment?

The decision to prescribe is based on the drug's approved indication for visceral smooth muscle spasm. Its focused peripheral action is a key differentiating feature, as it minimizes central nervous system side effects while targeting the pain source.


Q: What types of food or drinks should be avoided while taking Nu Spasm?

The official label specifically advises against co-administration with alcohol. This caution is in place because alcohol can increase the chance of certain side effects, such as dizziness, and may also increase the risk of liver damage due to the paracetamol component.


Q: Can Nu Spasm be safely taken with common allergy medications?

Official guidance states that co-administration with certain anticholinergic agents, which includes some antihistamines used for allergies, may lead to an additive intensification of anticholinergic effects. This potential interaction is noted in official warnings.


Q: What is the maximum duration of use described in official guidelines for Nu Spasm?

Regulatory documents constrain the use of this medicine to short-term episodes. It is officially not indicated for continuous daily use or for extended periods without proper medical investigation of the underlying cause of the spasm.


Q: What are the signs of an allergic reaction to Nu Spasm?

Official safety documents list allergic reactions, including common signs like skin rashes and hives. Rare, but severe reactions such as Stevens-Johnson syndrome have also been reported, and it is noted that any signs of hypersensitivity should be monitored.


Q: Is it common for Nu Spasm to be used in children?

Official use is permitted for oral tablets in children aged 6 years and over for routine use. However, official information states that the combination product is generally not recommended for children under 12 years of age.


Q: What is the risk profile of Nu Spasm compared to its intended benefit?

The official regulatory profile describes the intended spasmolytic benefit alongside defined serious risks. These risks include the potential for liver damage (due to the paracetamol component) and specific contraindications, which strictly define the safety boundaries of use.


Q: Is Nu Spasm effective for pain that is not related to spasms?

Nu Spasm is primarily indicated for pain that is directly associated with smooth muscle spasm. However, the medicine also contains Paracetamol/Acetaminophen, which is included to address general pain relief.


Q: What is the official guidance on taking Nu Spasm with other prescription medicines for chronic conditions?

Official documentation notes that Nu Spasm reduces gut motility. This effect means that the absorption and subsequent systemic effect of concurrently administered oral medications may be delayed or altered.


Q: What information should patients share with their doctor before starting Nu Spasm?

Official documents establish that the medicine is only appropriate if the patient does not have any contraindicated conditions, such as untreated narrow-angle glaucoma or myasthenia gravis. Specific caution is also noted for patients with heart or kidney impairment.


Q: How quickly does Nu Spasm usually start working?

Regulatory data on the drug's absorption, known as pharmacokinetics, indicate the expected rate of onset of effect. This information relates to the time it takes for the drug concentration to peak in the system following administration.


Q: How long does the effect of Nu Spasm typically last?

The duration of systemic exposure and effect is described by regulatory pharmacokinetics data. This is typically expressed by the drug’s elimination half-life, which indicates how long the drug remains active in the body.


Q: Is Nu Spasm suitable for use by older adults (seniors)?

Regulatory documents include specific statements if the medicine's effects or safety profile differ significantly in the elderly population. This may involve specific caution statements to reflect any differences in its safety profile for that group.


Q: What is the recommended approach if a dose of Nu Spasm is missed?

Patient Information Leaflets, which are based on regulatory approval, typically contain information regarding how to handle a missed dose, such as whether to skip it or take it as soon as it is remembered.


Q: Is it possible to become dependent on Nu Spasm?

Regulatory documentation, as part of the official drug label, must address the potential for dependence or abuse. This information is included to ensure the medicine is classified and used appropriately.


Q: Is Nu Spasm known to cause changes in weight?

Official documentation lists all known side effects in its safety profile sections. This record includes less common adverse reactions that have been reported, such as potential changes in weight.


Q: How long does it take for Nu Spasm to clear out of the system?

Regulatory pharmacokinetics data provides the elimination half-life, which indicates the rate at which the drug is cleared from the body. This information defines the timeline for the drug's removal from the system.


Q: Does the dosage of Nu Spasm change based on body weight?

Official dosing guidelines specify if administration rules are based on patient body weight or if they are standardized by age and route of administration. For Nu Spasm, the dosing rules are typically defined by age group and the form of the medicine used.


Q: What do official sources say about stopping Nu Spasm suddenly?

Regulatory documents include statements on the need for gradual discontinuation or the risks associated with abrupt cessation. This information is provided to clarify the risks associated with abruptly stopping the medicine.


Q: Have studies shown Nu Spasm to have any potential for misuse?

Regulatory documentation, as part of the official drug label, must address the potential for misuse and abuse. This information is legally required to ensure the medicine is classified and used responsibly.


Q: Does Nu Spasm affect laboratory blood tests?

Official documentation specifies if the medicine is known to interfere with the results of certain common laboratory tests.

How should Nu Spasm be stored and disposed of?

Storage and Disposal Instructions for Nu Spasm (Hyoscine Butylbromide)

Official regulatory documents define strict conditions for storing Nu Spasm to maintain stability. The product, in both tablet and injection forms, must be stored at a temperature not exceeding 30°C and should be protected from light. To ensure protection, the medicine must be kept in its original package.

  • Child Safety: Keep the medication out of the sight and reach of children.
  • Injection Handling: The solution for injection is strictly for single use only; any unused portion must be immediately discarded.
  • Disposal: Do not throw away unused or expired medicine via wastewater or household waste. Disposal must be performed in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nu Spasm found in:

A-Z Index: